openPR Logo
Press release

Oncology Drugs Market 2019 | Rapid Growth by Players Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer

08-14-2019 08:32 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Oncology Drugs

Oncology Drugs

Oncology Drugs

High cost of cancer drugs and adoption of alternative treatment options such as surgery and radiation therapy are major factors hindering the oncology drugs market growth. Several blockbuster oncology drugs in the market are expected to lose patent during 2018-2020, which is turn acts as an opportunities for emerging players in the global oncology drugs market.

Cancer is one of the deadliest disease with less chance of survival as the disease progresses. International Agency for Research on Cancer published GLOBOCAN 2018 report, which estimates cancer incidence and mortality rate. This report focus on geographic variability of cancer incidence rate and mortality rate across 20 world regions. This report projected 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. Therefore, high prevalence of cancer is expected to be major factor for growth of the global oncology drugs market.

Request Sample Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2332

According to a report by Pharmaceutical Research and Manufacturers Association in 2015, over 800 drugs are in development stage targeting various types of cancer. Moreover, same source suggested that around 73% of personalized medicine under development are targeted towards cancer. Melanoma, colorectal cancer, blood cancer, breast cancer, lung cancer, and prostate cancer are the most targeted cancer for drug development. According to International Federation of the Pharmaceutical Manufacturers Association’s report published in 2017, in 2014, the number of drugs in development for cancer was 1,919.

Increasing number of drugs are being approved for treating various types of cancer. According to U.S. FDA, around 16 new drugs were approved in 2017 for treatment of cancer. Moreover, by mid November 2018, eight more drugs were approved for cancer. Notable drug approvals from 2017 include,

Yescarta from Kite Pharmaceuticals that consist of the axicabtagene ciloleucel, for the treatment of relapsed or refractory large B-cell lymphomas (approved in October 2017)
Kymriah (tisagenlecleucel) from Novartis for the treatment of refractory B-cell precursor acute lymphoblastic leukemia (approved in August 2017)
Imfinzi (durvalumab) from AstraZeneca for the treatment of advanced or metastatic urothelial carcinoma and stage III non-small cell lung cancer (approved in May 2017)
Lorbrena (lorlatinib) Pfizer, for the treatment of ALK-positive metastatic non-small cell lung cancer (approved in November 2018)
Increasing number of blockbuster drugs going off patent is expected to boost entry of biosimilars and generic versions of oncology drugs.

Avastin (bevacizumab), which is a Humanized Monoclonal Antibody product for Colorectal, lung, breast, glioblastoma, kidney, and ovarian cancer by Roche is going off patent by July 2019 in U.S.
Erbitux (cetuximab), which is monoclonal antibody/ epidermal growth factor receptor inhibitor for treating colorectal cancer and head and neck cancer form Bristol-Myers Squibb and Eli Lilly and Company went off patent in 2016
Several biosimilars and generic drugs are launched in the market such as,

Mylan N.V. launched Mitomycin for Injection USP in March 2018 which is generic version of Bristol Myers Squibb's mutamycin indicated for stomach and pancreatic cancer, Samsung Bioepis (Biogen/Samsung)/Merck South Korea/U.S. launched Ontruzant (SB3) in September 2017 which is a biosimilar of trastuzumab indicated for breast cancer

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2332

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncology Drugs Market 2019 | Rapid Growth by Players Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer here

News-ID: 1822081 • Views:

More Releases from Coherent Market Insights

Magnesium Oxide Market Size 2024: New Opportunities, Geographical Analysis, and Forecast Until 2031 | Martin Marietta Materials Inc., Grecian Magnesite S.A., Premier Magnesia
Magnesium Oxide Market Size 2024: New Opportunities, Geographical Analysis, and …
The latest report published by Coherent Market Insights highlights the growth prospects of the Magnesium Oxide Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such
Colostrum Market Key Growth Drivers, Latest Opportunities, Increasing Demand, and Forecast By 2024-2031 | APS Biogroup, Biostrum Nutritech Pvt. Ltd.
Colostrum Market Key Growth Drivers, Latest Opportunities, Increasing Demand, an …
The latest report published by Coherent Market Insights highlights the growth prospects of the Colostrum Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such as
Steam Turbine Market Size 2024: Industrial Insights including Manufacturing Details and Forecast Till 2031 | General Electric (GE), Siemens Energy
Steam Turbine Market Size 2024: Industrial Insights including Manufacturing Deta …
The latest report published by Coherent Market Insights highlights the growth prospects of the Steam Turbine Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such
Protein Supplements Market Share: Size, Growth, Key Vendors, Trends, and Forecast From 2024-2031 | Mondelez Company, Meiji Holdings Co Ltd.
Protein Supplements Market Share: Size, Growth, Key Vendors, Trends, and Forecas …
The latest report published by Coherent Market Insights highlights the growth prospects of the Protein Supplements Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such

All 5 Releases


More Releases for Oncology

Immuno Oncology Assays Market Size, Immuno Oncology Assays Market Prediction, Im …
The Immuno Oncology Assays Market Report examines the Immuno Oncology Assays industry from a variety of angles, including market size, status, trends, and forecasts. It also gives a quick rundown of the top competitors and development opportunities in the market. The research contains a comprehensive study of the keyword market, split by companies, regions, types, and applications. The research goes into great detail on several aspects that have been studied as
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. International Oncology Summit will have an anticipated